ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
ADC Therapeutics (NYSE: ADCT) announced that CEO Chris Martin will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 8:30 a.m. ET. Investors can access a live webcast through the company's website, with a replay available for 30 days. ADC Therapeutics specializes in next-generation antibody drug conjugates (ADCs) for treating hematological malignancies and solid tumors. The company's FDA-approved ADC, ZYNLONTA™, targets relapsed diffuse large B-cell lymphoma, while Cami is under trial for Hodgkin lymphoma and advanced solid tumors.
- None.
- None.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021, at 8:30 a.m. ET.
A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA™ (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, the Company has multiple PBD-based ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005202/en/
FAQ
When will ADC Therapeutics' CEO present at the Jefferies Virtual Healthcare Conference?
Where can I watch the live presentation by ADC Therapeutics?
What is ZYNLONTA™, the ADC developed by ADC Therapeutics?
What clinical trials is ADC Therapeutics currently conducting?
What type of technology does ADC Therapeutics employ?
